A Product and Pipeline Analysis of the U.S. Multiple Sclerosis Therapeutics Market

 

Regular Price: USD 1,500

Special Price USD 1,125

25% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,125

PAY BY INVOICE

Be the first to review this product

The U.S. multiple sclerosis market is entering a new phase of growth driven by the development of innovative therapeutic platforms. Oral therapies are likely to revolutionize the treatment paradigm of multiple sclerosis by improving dosing and patient compliance.

This research service presents a marketed and pipeline analysis of the U.S. multiple sclerosis market. The purpose of this study is to highlight the current market landscape, provide a competitive analysis of all marketed and pipeline drugs as well as a pipeline analysis of all drugs in development for multiple sclerosis.

Table of Contents

A Product and Pipeline Analysis of the U.S. Multiple Sclerosis Therapeutics MarketAnalysis of the U.S. Multiple Sclerosis MarketExecutive SummaryIntroductionCompetitive LandscapeRRMS OverviewSPMS OverviewPPMS OverviewPRMS OverviewProduct ProfilesCertificationLegal DisclaimerAbout Frost & Sullivan




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.